Hemosil recombiplastin 2g

Manufactured by Werfen

Sourced in United States

HemosIL RecombiPlasTin 2G is a laboratory reagent used for the determination of prothrombin time (PT) in human plasma. It is a recombinant thromboplastin reagent for the quantitative determination of the extrinsic coagulation pathway.

Automatically generated - may contain errors

Lab products found in correlation

Hemosil synthasil, by Werfen (2 mentions) Acl top 500 analyzer, by Werfen (1 mentions) Hemosil reagents, by Werfen (1 mentions) Hemosil aptt sp, by Werfen (1 mentions) Technozym d dimer elisa, by Technoclone (1 mentions) Sta r evolution, by Diagnostica Stago (1 mentions) Acl elite pro, by Werfen (1 mentions) Hemosil fibrinogen c, by Werfen (1 mentions) Cellpack, by Sysmex (1 mentions) Xt 2000iv, by Sysmex (1 mentions) Acl top system, by Werfen (1 mentions) Aptt sp, by Werfen (1 mentions) Facsaria 2, by BD (1 mentions) Pool norm, by Diagnostica Stago (1 mentions)

11 protocols using hemosil recombiplastin 2g

Anticoagulation and Coronary Angiography Protocol

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

All measurements of INR, sCr, and TB were performed at the presentation of the patients prior to the initiation of anticoagulant therapy and coronary angiography. The blood-collection tubes contained 3.2% sodium citrate (0.5 ml citrate, 4.5 ml blood) for INR, measurement. Samples were immediately centrifuged for routine testing, and analysis was performed within 1 h after sampling. INR was measured using the reagent HemosIL RecombiPlasTin 2G (Instrumentation Laboratory, Bedford, MA, USA). Complete blood count was determined via an Abbott Cell-Dyn 3700 autoanalyzer using commercial assay kits (Abbott Diagnostic, CA, US). Biochemical measurements were performed using Siemens Healthcare Diagnostic Products kits and calibrators (Marburg, Germany).
The standard MELD score was calculated by using the following formula: 11.2 x (ln INR) + 0.378 x (ln total bilirubin) + 0.957 x (ln creatinine) + 0.643 [6 (link)].

Kırıs T., Avcı E, & Çelik A. (2018). Combined value of left ventricular ejection fraction and the Model for End-Stage Liver Disease (MELD) score for predicting mortality in patients with acute coronary syndrome who were undergoing percutaneous coronary intervention. BMC Cardiovascular Disorders, 18, 44.

+ Open protocol

+ Expand

Evaluation of the Q Smart Coagulation Analyzer

Check if the same lab product or an alternative is used in the 5 most similar protocols

The Q Smart system (Diagnostic Grifols, Barcelona, Spain) comprises the Q Smart analyzer and the following DG reagents (Diagnostic Grifols) for each test: DG-PT RecombiLIQ for prothrombin time (PT), DG-APTT Synth for activated partial thromboplastin time (APTT), DG-TT L Human for thrombin time (TT), DG-APTT Synth/DG-FVIII for FVIII, DG-Latex DDimer for d-dimer, and DG-Chrom AT L for Antithrombin(AT). ACL TOP 500 analyzer and Hemosil reagents from Instrumentation Laboratory (Bedford, Massachusetts) were used for comparison in the following tests: Hemosil Recombiplastin 2G for PT, Hemosil APTT-SP (liquid) for APTT, Hemosil Thrombin Time for TT, and Hemosil APTT-SP (liquid)/Hemosil FVIII Deficient Plasma for FVIII. For comparison in the d-dimer and AT tests, the BCS XP coagulometer and reagents were used (Siemens AG, Munich, Germany). Additionally, the PT assay was also performed with the CoaguChek XS point-of-care_POC (Roche, Indianapolis, Indiana).

Montalvão S.A., Francisco A.P., da Silva B.L., Huber S.C., Aguiari H.J., Fernandes M.C., Elidio P.S., Martinelli B.D., Tony I.M., Colella M.P, & Annichinno-Bizzachi J.M. (2020). From Hemophilia to Deep Venous Thrombosis Patient Samples: How to Perform an Easy Coagulometer Validation Process According to Available Guidelines. Clinical and Applied Thrombosis/Hemostasis, 26, 1076029620915512.

+ Open protocol

+ Expand

Cell-Block Preparation for SN-MM Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

For cell-block preparation, at least 1 × 10⁶ cells were harvested and processed as follows. Cell suspensions of SN-MM cell lines were centrifuged for 10 min at 3,000 rpm. A solution of plasma (100 mL, kindly provided by Centro Trasfusionale, ASST Spedali Civili) and HemosIL RecombiPlasTin 2G (200 mL, Instrumentation Laboratory; cat. no. 0020003050; 1:2) were added to cell pellets, mixed until the formation of a clot, then placed into a labeled cassette (Bio-Optica; cat. no. 07-7350). The samples were fixed in 10% formalin (Bio-Optica; cat. no. 05-K01004) for 1 h followed by paraffin inclusion.

Monti M., Benerini Gatta L., Bugatti M., Pezzali I., Picinoli S., Manfredi M., Lavazza A., Vanella V.V., De Giorgis V., Zanatta L., Missale F., Lonardi S., Zanetti B., Bozzoni G., Cadei M., Abate A., Vergani B., Balzarini P., Battocchio S., Facco C., Turri-Zanoni M., Castelnuovo P., Nicolai P., Fonsatti E., Leone B.E., Marengo E., Sigala S., Ronca R., Perego M., Lombardi D, & Vermi W. (2024). Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mTOR pathway in mucosal melanoma fitness. Journal of Translational Medicine, 22, 35.

+ Open protocol

+ Expand

Apixaban Pharmacokinetics and Coagulation Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Screening and EOS laboratory analysis were performed at the Clinical Institute of Laboratory Medicine, General Hospital Vienna, Austria, according to standard operating procedures. All other parameters were analyzed by Labcon GmbH (Vienna, Austria) using validated assays: ASSERACHROM^® β-TG test kit (Diagnostica Stago, Asniéres, France) for β-TG assessment, TAT was assessed using the Enzygnost^® TAT micro kit (Siemens GmbH, Munich, Germany), D-dimer was analyzed with the TECHNOZYM^® D-dimer ELISA (Technoclone, Vienna, Austria) and P-selectin was determined using the Human sP-selectin Platinum ELISA (eBioscience, CA). The detections ranges were 117.5 to 1880 U/mL for β-TG, 20 to 600 ng/mL for TAT, 189.7 to 1365 ng/mL for D-dimer, and 0.63 to 40 ng/mL for P-selectin.
Apixaban pharmacokinetics were assessed as anti-Xa activity with an ACL TOP500 coagulation analyser (Instrumentation Laboratory, Vienna, Austria) using apixaban as assay standard with a lower limit of quantification (LLQ) <10 ng/mL.
The ACL TOP500 coagulation analyzer was also used for aPTT and PT measurements using HemosIL^® SynthASil (Instrumentation Laboratory, Vienna, Austria; [aPTT]) and HemosIL^®RecombiPlasTin 2G (Instrumentation Laboratory, Vienna, Austria; [PT]) as reagents. The normal reference range for venous aPTT was 25.1 to 36.5 s and 70 to 130 % for venous PT.

Weisshaar S., Litschauer B., Bucher S., Riesenhuber M., Kapiotis S., Kyrle P.A, & Wolzt M. (2016). The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study. Medicine, 95(27), e4145.

+ Open protocol

+ Expand

Venous Blood Collection and INR Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The venous blood was drawn from patients who fasted within the first 24 h of admission for routine laboratory measurements including INR. The blood samples were obtained, preserved, and processed in a manner recommended by the clinical site laboratory's policies and procedures. The 3.2%citrate tubes are used and filled properly to maintain a blood/citrate ratio of 9/1. INR was measured on a STA-R EVOLUTION automated coagulation analyzer (Diagnostica Stago, Asnières, France) with an international sensitivity index of approximately 1.0 and using HemosIL RecombiPlasTin 2G as reagent (Instrumentation Laboratory, Bedford, MA, USA). The reference range of INR was roughly 0.9–1.1 in all clinical laboratories.

Xie X., Wang X., Li Z., Zhao X., Miao Z., Liu L., Li H., Meng X., Wang Y, & Wang Y. (2019). Prognostic Value of International Normalized Ratio in Ischemic Stroke Patients without Atrial Fibrillation or Anticoagulation Therapy. Journal of Atherosclerosis and Thrombosis, 26(4), 378-387.

+ Open protocol

+ Expand

Blood Coagulation Biomarker Measurements

Check if the same lab product or an alternative is used in the 5 most similar protocols

All the blood coagulation-related values were measured by LSI Medience Corporation (Tokyo, Japan). APTT, PT, and fibrinogen level were measured with HemosIL SynthASil (Instrumentation Laboratory, Bedford, MA, US); HemosIL RecombiPlasTin 2G (Instrumentation Laboratory); and HemosIL Fibrinogen-C (Instrumentation Laboratory), respectively. These three variables were measured using ACL ELITE PRO (Instrumentation Laboratory). Platelet counts were measured with cellpack (Sysmex, Hyogo, Japan) using XT-2000iV (Sysmex).

Obonai T., Fuchigami H., Furuya F., Kozuka N., Yasunaga M, & Matsumura Y. (2016). Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment. Scientific Reports, 6, 23613.

+ Open protocol

+ Expand

Automated Coagulation Analysis System

Check if the same lab product or an alternative is used in the 5 most similar protocols

The APTT-CWA was performed using APTT-SP^®, which uses silica as an activator of FXII and synthetic PLs (Instrumentation Laboratory) and PL, with an ACL-TOP^® system (Instrumentation Laboratory) as previously reported.^{12 (link),16 (link)} The CWA-sTF/FIXa was performed using PRP and 2,000-fold diluted HemosIL RecombiPlasTin 2G (TF concentration <0.1 pg/ml; Instrumentation Laboratory). Three types of curves are shown on the monitor of this system.^{12 (link)} One curve shows the changes in the absorbance observed while measuring the APTT, corresponding to fibrin formation (FF). The second (1st DP) corresponds to the coagulation velocity, and the third (2nd DP) corresponds to the coagulation acceleration. The height and time of the 1st DP, 2nd DP and FF are called the 1st DPH and 1st DPT, 2nd DPH and 2nd DPT, and FFH and FFT, respectively (Figure 1). PRP was prepared by centrifugation at 900 rpm for 15 minutes (platelet count, 40 × 10¹⁰/L), and PPP was prepared by centrifugation at 3,000 rpm for 15 minutes (platelet count, <0.5 × 10¹⁰/L).^{21 (link)}

Hasegawa M., Tone S., Wada H., Naito Y., Matsumoto T., Yamashita Y., Shimaoka M, & Sudo A. (2021). The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients. Clinical and Applied Thrombosis/Hemostasis, 27, 10760296211012094.

+ Open protocol

+ Expand

Procoagulant Activity of MonoMac 1 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human monocytic cell line MonoMac 1 (MM1) was exposed to immunoglobulin fractions and procoagulant activity was determined as previously described.¹⁴ Based on a standard curve of recombinant tissue factor (TF; hemosIL RecombiPlasTin 2G, #0020003051, Instrumentation Laboratory, Munich, Germany) clotting times were converted into procoagulant activity (PCA) units.

Hollerbach A., Müller‐Calleja N., Pedrosa D., Canisius A., Sprinzl M.F., Falter T., Rossmann H., Bodenstein M., Werner C., Sagoschen I., Münzel T., Schreiner O., Sivanathan V., Reuter M., Niermann J., Galle P.R., Teyton L., Ruf W, & Lackner K.J. (2022). Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19. Journal of Thrombosis and Haemostasis, 19(9), 2335-2347.

+ Open protocol

+ Expand

Isolation and Characterization of PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fresh PBMCs were isolated from buffy of healthy donor coat by density centrifugation using cat. no. 307618, Biolegend) and sorted using FACSAria II (BD Biosciences). Accordingly, PBMCs were subjected to doublets exclusion and subsequently gated on lymphocytes negative (CD3, CD19 and CD56) and HLA-DR positive cells, finally monocytes were positively selected as CD14 + CD16 - or CD14 -CD16 + whereas BDCA1 + were negatively selected as CD14 -CD16 -CD141 -and CD303 -.
Fluorescence negative controls were performed using intra-simple negative populations as reference.
For cell block preparation, cell suspensions of sorted cells were centrifuged for 10 minutes at 3,000 rpm. A solution of plasma (100 mL, kindly provided by Centro Trasfusionale, ASST Spedali Civili) and HemosIL RecombiPlasTin 2G (200 mL, Instrumentation Laboratory; cat. no. 0020003050; 1:2) were added to cell pellets, mixed until the formation of a clot, then placed into a bio-cassette (Bio-Optica; cat. no. 07-7350). The specimen was fixed in 10% formalin (Bio-Optica; cat. no. 05-K01004) for 1 hour followed by paraffin inclusion.

Lonardi S., Scutera S., Licini S., Lorenzi L., Cesinaro A.M., Gatta L.B., Castagnoli C., Bollero D., Sparti R., Tomaselli M., Medicina D., Calzetti F., Cassatella M.A., Facchetti F., Musso T, & Vermi W. (2020). CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis. Cancer immunology research, 8(6).

+ Open protocol

+ Expand

Clotting Time Assay for EA.hy926 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

After stimulation with histones for 4 h, EA.hy926 cells were harvested. Cells were resuspended to 5 x 10⁶/mL in PBS and 20 μL of cell suspension was added in a cuvette. The plasma (80 μL; Pool Norm; Diagnostica Stago, Asnieres, France) which was anticoagulated with 3.2% sodium citrate was mixed with the cell suspension and the formation of a clot was induced by the addition of 100 μL of pre-warmed 0.025 M CaCl₂. The clotting time was measured by ST Art (Diagnostica Stago). The standard curve was produced using HemosIL RecombiPlasTin 2G (Instrumentation Laboratory, Bedford, MA, USA).

Kim J.E., Yoo H.J., Gu J.Y, & Kim H.K. (2016). Histones Induce the Procoagulant Phenotype of Endothelial Cells through Tissue Factor Up-Regulation and Thrombomodulin Down-Regulation. PLoS ONE, 11(6), e0156763.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!